The second session of the World Stem Cell Summit in Atlanta moved past all the promising science and right to the nitty-gritty of making cell-based therapies common. Four panelists reminded the audience that while they too are super excited by the potential for this field, unless folks developing therapies think about reimbursement early those therapies … Continue reading The bottom line: stem cell therapies will never be widely available if insurers won’t pay for them
Pharmaceutical industry
Global stem cell market predicted to reach $40 billion in five years, even bigger when mixed with new technologies
The global consulting firm Frost and Sullivan held a webinar yesterday in which they noted health care systems everywhere are facing an increasing challenge of costly chronic care. They suggested health care providers have started to embrace regenerative medicine as a viable alternative. Because of its power to change the course of disease, the consultants … Continue reading Global stem cell market predicted to reach $40 billion in five years, even bigger when mixed with new technologies
Moving Beyond Current CIRM Funding
Delivering on CIRM’s mission of “accelerating stem cell treatments to patients with unmet medical needs” requires the participation of multiple stakeholders to span the research, development, and commercialization phases of bringing a new product to market. In this post, I am pleased to highlight two recent examples of CIRM-funded projects moving beyond their period of … Continue reading Moving Beyond Current CIRM Funding
Partnering with Big Pharma to benefit patients
Our mission at CIRM is to accelerate the development of stem cell therapies for patients with unmet medical needs. One way we have been doing that is funding promising research to help it get through what’s called the “Valley of Death.” This is the time between a product or project showing promise and the time … Continue reading Partnering with Big Pharma to benefit patients
The Stem Cellar 